Table 2.
Screening for infectious disease in study population.
| all MS patients | all non-naïve MS patients | ||||
|---|---|---|---|---|---|
| all MS patients (n = 174) | naïve (n = 66) |
non-naïve (n = 108) |
switcher (n = 91) |
non-switcher (n = 17) |
|
| HAV | 58/174 | 22/66 | 35/108 | 33/91 | 2/17 |
| IgG + IgM- | 15/57 | 6/22 | 9/35 | 8/33 | 1/1 |
| IgG-IgM- | 43/57 | 16/22 | 26/35 | 25/33 | 1/1 |
| HBV | 142/174 | 51/66 | 90/108 | 80/91 | 10/17 |
| HBsAg- HBsAb + anti-HBc- | 41/141 | 19/50 | 21/90 | 19/80 | 2/10 |
| HBsAg- HBsAb + anti-HBc + | 18/141 | 5/50 | 13/90 | 10/80 | 3/10 |
| HBsAg- HBsAb- anti-HBc- | 83/141 | 27/50 | 56/90 | 51/80 | 5/10 |
| HCV-Ab | 108/174 | 44/66 | 64/108 | 59/91 | 5/17 |
| positive | 4/108 | 1/43 | 3/64 | 3/59 | 0/5 |
| negative | 104/108 | 42/43 | 61/64 | 56/59 | 5/5 |
| HIV Ab/Ag | 172/174 | 66/66 | 108/108 | 91/91 | 17/17 |
| positive | 0/172 | 0/66 | 0/108 | 0/91 | 0/15 |
| negative | 172/172 | 66/66 | 106/108 | 91/91 | 17/17 |
| Measle | 100/174 | 36/66 | 64/108 | 57/91 | 7/17 |
| IgG + IgM- | 94/100 | 34/35 | 60/64 | 54/57 | 6/7 |
| IgG-IgM- | 6/100 | 2/35 | 4/35 | 3/57 | 1/7 |
| Rubella | 126/174 | 44/66 | 81/108 | 74/91 | 7/17 |
| IgG + IgM- | 108/125 | 36/43 | 71/81 | 65/74 | 6/7 |
| IgG-IgM- | 18/125 | 8/43 | 10/71 | 9/74 | 1/7 |
| Toxoplasma | 128/174 | 47/66 | 80/108 | 73/91 | 7/17 |
| IgG + IgM- | 30/127 | 8/46 | 22/80 | 19/73 | 3/7 |
| IgG-IgM- | 98/127 | 39/46 | 58/80 | 54/73 | 4/7 |
| CMV | 130/174 | 48/66 | 81/108 | 74/91 | 7/17 |
| IgG + IgM- | 87/129 | 31/47 | 55/81 | 50/74 | 5/7 |
| IgG-IgM- | 43/129 | 17/47 | 26/81 | 24/74 | 2/7 |
| HSV-1 | 113/174 | 43/66 | 70/108 | 61/91 | 9/17 |
| IgG + IgM- | 84/112 | 32/42 | 52/70 | 48/61 | 4/9 |
| IgG + IgM + | 2/112 | 0/42 | 2/70 | 0/61 | 2/9 |
| IgG-IgM- | 27/112 | 11/42 | 16/70 | 15/61 | 1/9 |
| HSV-2 | 112/174 | 42/66 | 70/108 | 61/91 | 9/17 |
| IgG + IgM- | 14/112 | 3/41 | 11/70 | 11/61 | 0/9 |
| IgG-IgM- | 98/112 | 39/41 | 59/70 | 50/61 | 9/9 |
| VZV | 116/174 | 43/66 | 73/108 | 64/91 | 9/17 |
| IgG + IgM- | 114/116 | 43/42 | 71/73 | 62/64 | 9/9 |
| IgG-IgM- | 2/116 | 0/42 | 2/73 | 2/64 | 0/9 |
| EBV | 133/174 | 49/66 | 83/108 | 75/91 | 8/17 |
| VCA IgG + EBNA IgG + VCA IgM- | 131/132 | 48/48 | 81/83 | 73/75 | 8/8 |
| VCA IgG + EBNA IgG- VCA IgM- | 2/132 | 0/48 | 2/83 | 2/75 | 0/8 |
| VCA IgG- EBNA IgG- VCA IgM- | 0/132 | 0/48 | 0/83 | 0/75 | 0/8 |
| JCV Stratify® assay | 33/174 | 12/66 | 21/108 | 16/94 | 5/17 |
| positive | 5/33 | 0/12 | 5/21 | 4/5 | 1/4 |
| negative | 28/33 | 12/12 | 16/21 | 12/16 | 4/5 |
| QuantiFERON® TB-gold | 127/174 | 47/66 | 80/108 | 69/91 | 11/17 |
| positive | 19/127 | 4/47 | 15/80 | 11/71 | 4/11 |
| indeterminate | 3/127 | 2/47 | 1/80 | 1/71 | 0/11 |
| negative | 105/127 | 13/47 | 64/80 | 57/71 | 7/15 |
MS: multiple sclerosis; HAV: hepatitis A virus; HBV: hepatitis B virus, HCV: hepatitis C virus; HIV: human immunodeficiency virus; Ab: antibody; Ag: antigen; CMV: cytomegalovirus; HSV-1: Herpes Simplex-1; HSV-2: Herpes Simplex-2; VZV: varicella zoster virus; EBV: Epstein-Barr virus; JCV: John Cunningham virus.